Found: 11
Select item for more details and to access through your institution.
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 20, p. 12196, doi. 10.3390/ijms232012196
- By:
- Publication type:
- Article
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.
- Published in:
- Translational Psychiatry, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41398-023-02473-8
- By:
- Publication type:
- Article
Esmethadone-HCl (REL-1017): a promising rapid antidepressant.
- Published in:
- European Archives of Psychiatry & Clinical Neuroscience, 2023, v. 273, n. 7, p. 1463, doi. 10.1007/s00406-023-01571-4
- By:
- Publication type:
- Article
REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study.
- Published in:
- Frontiers in Pharmacology, 2021, v. 11, p. N.PAG, doi. 10.3389/fphar.2021.671859
- By:
- Publication type:
- Article
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.863959
- By:
- Publication type:
- Article
REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.863959
- By:
- Publication type:
- Article
Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 2, p. 341, doi. 10.1007/s40268-024-00477-3
- By:
- Publication type:
- Article
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism.
- Published in:
- Drugs in R&D, 2024, v. 24, n. 1, p. 51, doi. 10.1007/s40268-023-00450-6
- By:
- Publication type:
- Article
REL-1017 (esmethadone; d-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-15055-3
- By:
- Publication type:
- Article
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 8, p. 997, doi. 10.3390/ph15080997
- By:
- Publication type:
- Article
The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin.
- Published in:
- Pharmaceuticals (14248247), 2022, v. 15, n. 7, p. N.PAG, doi. 10.3390/ph15070882
- By:
- Publication type:
- Article